News Changing Faces: biopharma hires from November 2022 The month of November saw a number of notable hires and personnel moves in biotech and
News Atriva takes MEK inhibitor into phase 2 for COVID-19 Atriva Therapeutics is starting a phase 2 trial of its MEK inhibitor ATR-002 in patients with coronavirus infections, saying the drug could help prevent patients progressing to
News NIH abandons trial of SIGA's mpox drug Another clinical trial has found that SIGA Technologies' antiviral drug TPOXX (tecovirimat) is ineffective as a treatment for mpox.
Digital Sponsored The AI effect in pharma commercial strategy: From data to re... Discover how AI is transforming the pharma commercial strategy. Unlock real-time insights & actions from data. Click here for more.
